Differences
Pro-tip: Use show current snapshot tab to visualise what will be ignored.
Toggle navigation * About * Team * Portfolio * News * Contact Portfolio Aisling Capital invests in products, technologies and businesses that advance health. In addition to investing in companies developing pharmaceutical, biotechnology and medical products, Aisling invests in businesses that provide drug development, manufacturing and other important services to the healthcare industry. Portfolio Companies * All * Sector + Biopharma + Consumer + Diagnostics + Medical Device + Services * Geographic Area + Ex-US + Mid-Atlantic + Midwest + Mountain + New England + South + West Coast * Status + Current + Historic * Aclaris Therapeutics, Inc. NasdaqGS: ACRS Specialty pharmaceutical company, focusing on identifying, developing, and commercializing topical drugs to address various needs in dermatology. + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location Malvern, PA + Website https://aclaristx.com/ * Adams Respiratory Therapeutics, Inc. Specialty pharmaceutical company engaged in the development, commercialization and marketing of over-the-counter and prescription drugs for the treatment of respiratory disorders + Year Invested 2001 + Fund I + Sector Consumer + Company Status acquired + Investment Status historic + Location Chester, NJ + Website https://rb.com/ * ADMA Biologics, Inc. NasdaqCM:ADMA Biopharmaceutical company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of infectious diseases + Year Invested 2007 + Fund II + Sector Biopharma + Company Status public + Investment Status current + Location Ramsey, NJ + Website https://admabiologics.com/ * Advion, Inc. Provider of bioanalytical testing equipment to the pharmaceutical industry + Year Invested 2002 + Fund I + Sector Services + Company Status private + Investment Status historic + Location Ithaca, NY + Website https://advion.com/ * Aeglea BioTherapeutics, Inc. NasdaqGM:AGLE Biopharmaceutical company developing human enzyme therapeutics for rare genetic diseases + Year Invested 2018 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location Austin, TX + Website https://aegleabio.com/ * Agile Therapeutics, Inc. NasdaqGM:AGRX Women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products + Year Invested 2012 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location Princeton, NJ + Website https://agiletherapeutics.com/ * Aimmune Therapeutics, Inc. NasdaqGS:AIMT Biopharmaceutical company developing desensitization treatments for food allergies + Year Invested 2015 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location Brisbane, CA + Website https://aimmune.com/ * Ajax Health Medical device platform building a diversified portfolio of emerging medical device companies + Year Invested 2017 + Fund IV + Sector Medical Device + Company Status private + Investment Status current + Location Menlo Park, CA + Website https://ajaxhealth.com/ * Allos Therapeutics, Inc. Biopharmaceutical company engaged in the development and commercialization of anti-cancer therapeutics + Year Invested 2002 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location Westminster, CO + Website https://sppirx.com/ * Ambit Biosciences Corporation Biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat oncology, autoimmune and inflammatory diseases + Year Invested 2001 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location San Diego, CA + Website https://ambitbio.com/ * Antios Therapeutics Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases. Antios is currently developing ATI-2173, aiming to provide chronic hepatitis B-infected patients with a curative combination regimen. + Year Invested 2021 + Fund V + Sector Biopharma + Company Status private + Investment Status historic + Location Atlanta, GA + Website https://antiostherapeutics.com/ * Aragon Pharmaceuticals, Inc. Oncology drug development company focused on novel therapeutics for prostate and breast cancer + Year Invested 2010 + Fund III + Sector Biopharma + Company Status acquired + Investment Status historic + Location New Brunswick, NJ + Website https://jnj.com/ * Archimica Cooperatief U.A. Manufacturer of active pharmaceutical ingredients and late state intermediates for the pharmaceutical industry + Year Invested 2006 + Fund II + Sector Services + Company Status acquired + Investment Status historic + Location Amsterdam, Netherlands + Website euticals.com * Arcus Biosciences, Inc. NYSE:RCUS Biotechnology company developing cancer immunotherapies targeting the adenosine and other oncology pathways + Year Invested 2017 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location Hayward, CA + Website https://arcusbio.com/ * ARMGO Pharma, Inc. Biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics to treat debilitating cardiac, muscular and neurological disorders + Year Invested 2006 + Fund II + Sector Biopharma + Company Status private + Investment Status current + Location Tarrytown, NY + Website http://armgo.com/ * ARMO BioSciences, Inc. NasdaqGS:ARMO Biotechnology company developing immuno-oncology therapies in combination with standard of care or emerging immunotherapies + Year Invested 2018 + Fund IV + Sector Biopharma + Company Status acquired + Investment Status historic + Location Redwood City, CA + Website armobio.com * Ascendis Pharma A/S NasdaqGS:ASND Endocrine-focused biopharmaceutical company developing long-acting human growth hormone for the treatment of pediatric growth hormone deficiency + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location Hellerup, Denmark + Website https://ascendispharma.com/ * Aton Pharma, Inc. Biotechnology company focused on the development of novel treatments for cancer + Year Invested 2002 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location Tarrytown, NY + Website https://merck.com/ * Atreca, Inc. NasdaqGS:BCEL Biotechnology company developing novel oncology therapeutics based on a deep understanding of the human immune response + Year Invested 2018 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location Redwood City, CA + Website https://atreca.com/ * Audentes Therapeutics, Inc. NasdaqGM:BOLD Biotechnology company developing gene therapy-based treatments in several serious, rare diseases + Year Invested 2017 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location San Francisco, CA + Website https://audentestx.com/ * Auxilium Pharmaceuticals, Inc. NasdaqGS:AUXL Specialty pharmaceutical company that develops and markets pharmaceutical products for urology and sexual health + Year Invested 2003 + Fund I + Sector Biopharma + Company Status public + Investment Status historic + Location Chesterbrook, PA + Website auxilium.com * AVANZA Laboratories, LLC Contract research organization that provides GLP complaint drug development services for biotechnology and pharmaceutical firms, and government agencies + Year Invested 2009 + Fund II + Sector Services + Company Status acquired + Investment Status historic + Location Gaithersburg, MD + Website smithersavanza.com * AVROBIO, Inc. NasdaqGS:AVRO Biotechnology company developing lentiviral-based gene therapies to treat lysosomal storage disorders (LSDs) + Year Invested 2018 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location Cambridge, MA + Website https://avrobio.com/ * Axcan Pharma, Inc. Specialty pharmaceutical company focused on the treatment of gastrointestinal disorders + Year Invested 2000 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location Quebec, Canada + Website actavis.com * Barrier Therapeutics, Inc. Specialty pharmaceutical company focused on development and commercialization of dermatology drugs + Year Invested 2002 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location Princeton, NJ + Website http://stiefel.com/ * Bicara Therapeutics Bicara Therapeutics developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. + Year Invested 2023 + Fund V + Sector Biopharma + Company Status private + Investment Status current + Location Cambridge, MA + Website https://bicara.com/ * Bioenvision, Inc. Biotechnology company focused on the development and commercialization of drugs to treat oncology and infectious disease + Year Invested 2002 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location New York, NY + Website genzyme.com * Biohaven Pharmaceuticals Ltd. NYSE:BHVN Biopharmaceutical company developing treatments for orphan neurologic indications and other areas of large unmet medical needs + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location New Haven, CT + Website https://biohavenpharma.com/ * Biomea Fusion, Inc. NasdaqGM:BMEA Biomea Fusion is a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers. Leveraging its extensive expertise in irreversible binding chemistry and development, the Company built its proprietary FUSION System discovery platform to advance a pipeline of novel irreversible, small molecule therapies. The lead product candidate, BMF-219, is an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Biomea Fusion’s goal is to utilize its capabilities and platform to become a leader in developing irreversible small molecules in order to maximize the depth and durability of clinical benefit when treating various cancers. + Year Invested 2020 + Fund V + Sector Biopharma + Company Status public + Investment Status current + Location Redwood City, CA + Website https://biomeafusion.com/ * BridgeBio Pharma LLC NasdaqGS:BBIO Orphan disease drug platform with a robust portfolio of transformative drug programs that address rare diseases across oncology, cardiology, dermatology, neurology and endocrinology + Year Invested 2017 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location Palo Alto, CA + Website https://bridgebio.com/ * Cardiokine, Inc. Biotechnology company developing drugs for the treatment and prevention of cardiovascular diseases + Year Invested 2004 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location Philadelphia, PA + Website https://chiesiusa.com/ * Catalent, Inc. NYSE:CTLT Provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products + Year Invested 2007 + Fund II + Sector Services + Company Status public + Investment Status historic + Location Somerset, NJ + Website https://catalent.com/ * Cempra, Inc. NasdaqGS:CEMP Drug discovery and development company focused on infectious diseases and the treatment of drug-resistant bacteria + Year Invested 2006 + Fund II + Sector Biopharma + Company Status public + Investment Status historic + Location Chapel Hill, NC + Website cempra.com * Chimerix, Inc. NasdaqGM:CMRX Biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need + Year Invested 2013 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location Durham, NC + Website https://chimerix.com/ * Cidara Therapeutics, Inc. NasdaqGM:CDTX Drug discovery and development company focused on devastating fungal infections that often complicate cancer and transplant treatments + Year Invested 2008 + Fund II + Sector Biopharma + Company Status public + Investment Status historic + Location San Diego, CA + Website https://cidara.com/ * Clovis Oncology, Inc. NasdaqGS:CLVS Biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents + Year Invested 2011 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location Boulder, CO + Website https://clovisoncology.com/ * CollaGenex Pharmaceuticals, Inc. Specialty pharmaceutical company that develops and markets proprietary medical therapies to the dermatology market + Year Invested 2001 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location Newton, PA + Website https://galderma.com/ * Colorescience, Inc. Cosmetics company that manufactures and sells mineral-based products + Year Invested 2012 + Fund I + Sector Consumer + Company Status acquired + Investment Status historic + Location Carlsbad, CA + Website https://colorescience.com/ * COMPASS Pathways NASDAQGS: CMPS COMPASS Pathways is a mental health biotechnology company pioneering the development of a new model of psilocybin treatment, in which their proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. + Year Invested 2023 + Fund V + Sector Biopharma + Company Status public + Investment Status current + Location London, UK + Website https://compasspathways.com/ * Cynapsus Therapeutics Inc. NasdaqGM:CYNA Specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson’s disease + Year Invested 2015 + Fund III + Sector Biopharma + Company Status acquired + Investment Status historic + Location Toronto, Canada + Website https://cynapsus.ca/ * Cytos Biotechnology AG SWX:CYTN Biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform + Year Invested 2012 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location Schlieren, Switzerland + Website cytos.com * Dermira, Inc. NasdaqGS:DERM Specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients + Year Invested 2014 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location Redwood City, CA + Website https://dermira.com/ * + Year Invested 2022 + Fund V + Sector Biopharma + Company Status private + Investment Status current + Location Foster City, CA + Website https://drenbio.com/ * Durata Therapeutics, Inc. Pharmaceutical company focused on the development and commercialization of differentiated therapeutic solutions for physicians and providers to advance patient care in infectious disease and acute illnesses + Year Invested 2009 + Fund III + Sector Biopharma + Company Status acquired + Investment Status historic + Location Chicago, IL + Website duratatherapeutics.com * EarLens Corporation Medical device company committed to providing hearing impaired patients a hearing solution that is designed to change the current standard of care for sound performance. + Year Invested 2014 + Fund III + Sector Medical Device + Company Status private + Investment Status historic + Location Menlo Park, CA + Website https://earlens.com/patients/ * Eidos Therapeutics NasdaqGS:EIDX Biopharmaceutical company developing therapies to treat transthyretin amyloidosis (ATTR), primarily in the heart + Year Invested 2018 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location San Francisco, CA + Website https://eidostx.com/ * Elevation Oncology, Inc. NasdaqGM:ELEV Elevation Oncology is a clinical-stage oncology company developing targeted therapies for genetically driven cancers. Elevation's lead product candidate, seribantumab, a HER3 monoclonal antibody, is enrolling a Phase 2 registrational trial for NRG1 fusion-driven cancers. + Year Invested 2019 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location New York, NY + Website https://elevationoncology.com/ * Esperion Therapeutics, Inc. NasdaqGM:ESPR Drug discovery and development company focused on therapies that prevent, treat and reverse cardiovascular and metabolic diseases + Year Invested 2008 + Fund II + Sector Biopharma + Company Status public + Investment Status historic + Location Ann Arbor, MI + Website https://esperion.com/ * F2G Limited Antifungal drug discovery and development company focused on novel therapies to treat life threatening invasive fungal infections + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status private + Investment Status historic + Location Manchester, UK + Website https://f2g.com/ * + Year Invested 2022 + Fund V + Sector Biopharma + Company Status private + Investment Status current + Location Grove City, OH + Website https://forgebiologics.com/ * Garuda Therapeutics, Inc. Garuda Therapeutics seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants. Garuda's platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible and transgene-free blood stem cell therapies. Like bone marrow transplants, Garuda's technology could provide potentially curative therapies for more than 70 diseases. + Year Invested 2021 + Fund V + Sector Biopharma + Company Status private + Investment Status current + Location Cambridge, MA + Website garudatx.com * Global Blood Therapeutics, Inc. NasdaqGS:GBT Biopharmaceutical company developing novel therapies to improve the lives of patients with serious blood-based disorders + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location South San Francisco, CA + Website https://gbt.com/ * GTx, Inc. NasdaqCM:GTXI Biopharmaceutical company targeting hormone pathways to treat stress urinary incontinence (SUI) in women + Year Invested 2017 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location Memphis, TN + Website gtxinc.com * Harmony Biosciences, LLC NasdaqGM:HRMY Biopharmaceutical company developing and commercializing innovative drugs to address unmet needs for patients with sleep and CNS disorders + Year Invested 2018 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location Plymouth Meeting, PA + Website https://harmonybiosciences.com/ * Ibrutinib Royalty Anti-cancer drug targeting B-cell malignancies + Year Invested 2013 + Fund III + Sector Biopharma + Company Status private + Investment Status historic + Location N/A + Website https://imbruvica.com/ * Infinity Pharmaceuticals, Inc. NasdaqGS:INFI Biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to patients with difficult-to-treat diseases + Year Invested 2012 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location Cambridge, MA + Website https://infi.com/ * Intercept Pharmaceuticals, Inc. NasdaqGS:ICPT Biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing our proprietary bile acid chemistry + Year Invested 2012 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location New York, NY + Website https://interceptpharma.com/ * Intersect ENT, Inc. NasdaqGM:XENT Commercial stage drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions + Year Invested 2014 + Fund III + Sector Medical Device + Company Status public + Investment Status historic + Location Menlo Park, CA + Website propelopens.com * LENSAR, Inc. Leader in next-generation femtosecond laser technology for refractive cataract surgery + Year Invested 2008 + Fund II + Sector Medical Device + Company Status private + Investment Status historic + Location Orlando, FL + Website https://lensar.com/ * Lombard Medical, Inc. NasdaqGM:EVAR Medical technology company specializing in developing, manufacturing and marketing endovascular stent-grafts that address significant unmet needs in the repair of aortic aneurysms + Year Invested 2014 + Fund III + Sector Medical Device + Company Status public + Investment Status historic + Location Oxfordshire, UK + Website https://lombardmedical.com/ * Loxo Oncology, Inc. NasdaqGM:LOXO Biotechnology company developing targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations + Year Invested 2013 + Fund III + Sector Biopharma + Company Status acquired + Investment Status historic + Location Stamford, CT + Website https://loxooncology.com/ * MAP Pharmaceuticals, Inc. Specialty pharmaceutical company developing new therapies based on proprietary drug particle and inhalation technologies + Year Invested 2003 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location Mountain View, CA + Website https://allergan.com/ * Marker Therapeutics, Inc. NasdaqCM:MRKR Biotechnology company developing next-generation T cell-based immunotherapies for cancer + Year Invested 2018 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location Houston, TX + Website https://markertherapeutics.com/ * MKG LLC Medical Knowledge Group is comprised of best-in-class medical communications, health care consulting, and data analytics companies. Guided by strategic insight, creative innovation, and medical acumen, MKG companies specialize in distinct service areas within the health care marketing and communications sector. + Year Invested 2019 + Fund V + Sector Services + Company Status private + Investment Status historic + Location New York, NY + Website https://mkgny.com/ * MEI Pharma, Inc. NasdaqCM:MEIP Oncology company focused on the clinical development of novel therapies for cancer + Year Invested 2013 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location San Diego, CA + Website meipharma.com * Menlo Therapeutics Inc. NasdaqGS:MNLO Biopharmaceutical company developing an oral therapy for the treatment of chronic pruritus associated with various conditions and chronic cough + Year Invested 2017 + Fund IV + Sector Biopharma + Company Status private + Investment Status historic + Location Menlo Park, CA + Website menlotherapeutics.com * Mindful Health Solutions + Year Invested 2024 + Fund V + Sector Services + Company Status private + Investment Status current + Location San Francisco, CA + Website https://mindfulhealthsolutions.com/ * Miramar Labs, Inc. OTC:MRLB Medical device company focused on developing products for dermatologic medical conditions + Year Invested 2011 + Fund III + Sector Medical Device + Company Status acquired + Investment Status historic + Location Sunnyvale, CA + Website https://miradry.com/ * Monte Rosa Therapeutics, Inc. NasdaqGM:GLUE Monte Rosa Therapeutics is a biotechnology company developing molecular glues to degrade disease-causing proteins. The company has developed a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. + Year Invested 2020 + Fund V + Sector Biopharma + Company Status public + Investment Status current + Location Boston, MA + Website https://monterosatx.com/ * Myogen, Inc. Biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders + Year Invested 2001 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location Westminster, CO + Website https://gilead.com/ * Nabriva NasdaqGM:NBRV Biopharmaceutical company developing new antibiotics to treat infectious diseases + Year Invested 2018 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location King of Prussia, PA + Website https://nabriva.com/ * NextWave Pharmaceuticals, Inc. Specialty pharmaceutical company developing extended release OTC and prescription products for children and adults + Year Invested 2007 + Fund II + Sector Biopharma + Company Status acquired + Investment Status historic + Location Cupertino, CA + Website https://pfizer.com/ * Novazyme Pharmaceuticals, Inc. Biotechnology company focused on drugs to treat lysosomal storage diseases + Year Invested 2000 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location Princeton, NJ + Website https://sanofigenzyme.com/ * Nuvation Bio, Inc. NasdaqGM:NUVB Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. + Year Invested 2019 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location New York, NY + Website https://nuvationbio.com/ * ObsEva SA NasdaqGS:OBSV Biopharmaceutical company developing novel therapeutics in women's health for the treatment of symptoms associated with endometriosis and uterine fibroids + Year Invested 2017 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location Geneva, Switzerland + Website https://obseva.com/ * Oculex Pharmaceuticals, Inc. Ophthalmic drug delivery company with platform technology to facilitate the treatment of major sight-threatening eye diseases and conditions + Year Invested 2002 + Fund I + Sector Medical Device + Company Status acquired + Investment Status historic + Location Sunnyvale, CA + Website https://allergan.com/ * Paratek Pharmaceuticals, Inc. NasdaqGM:PRTK Biopharmaceutical company engaged in the discovery, development and commercialization of antibiotics to save lives and alleviate suffering + Year Invested 2007 + Fund II + Sector Biopharma + Company Status public + Investment Status historic + Location Boston, MA + Website https://paratekpharma.com/ * PellePharm Biotechnology company developing topical therapeutics targeting rare dermatological diseases + Year Invested 2018 + Fund IV + Sector Biopharma + Company Status private + Investment Status historic + Location San Francisco, CA + Website https://pellepharm.com/ * Pernix Therapeutics, Inc. NasdaqGM:PTX Specialty pharmaceutical company primarily focused on the sales, marketing and development of branded pharmaceutical products + Year Invested 2011 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location Houston, TX + Website pernixtx.com * Pharmaron, Inc. Provider of research and development services for pharmaceutical and biotechnological industries worldwide + Year Invested 2006 + Fund II + Sector Services + Company Status private + Investment Status historic + Location Beijing, China + Website https://pharmaron.com/ * Planet Biopharmaceuticals, Inc. Developer and manufacturer of allergenic extracts and other products for the treatment and prevention of allergy + Year Invested 2007 + Fund II + Sector Consumer + Company Status acquired + Investment Status historic + Location Liberty, MO + Website areslifesciences.com * Poseida Therapeutics, Inc. NasdaqGS:PSTX Biopharmaceutical company developing next-generation CAR-T therapies for hematological cancers and solid tumors. + Year Invested 2019 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location San Diego, CA + Website https://poseida.com/ * PowerVision, Inc. Developer of a fluid-controlled intraocular lens + Year Invested 2014 + Fund III + Sector Medical Device + Company Status acquired + Investment Status historic + Location Belmont, CA + Website powervisionlens.com * PreCision Dermatology, Inc. Specialty pharmaceutical company developing, manufacturing and marketing prescription and consumer dermatology products + Year Invested 2012 + Fund III + Sector Biopharma + Company Status acquired + Investment Status historic + Location Cumberland, RI + Website valeant.com * Prolacta Bioscience, Inc. Biopharmaceutical company developing and marketing human milk-based nutritional products for premature infants in the neonatal intensive care unit + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status private + Investment Status current + Location City of Industry, CA + Website https://prolacta.com/ * Promentis Pharmaceuticals, Inc. Biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system disorders of System XC- + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status private + Investment Status current + Location Milwaukee, WI + Website https://promentispharma.com/ * Protagonist Therapeutics, Inc. NasdaqGM:PTGX Clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs in inflammatory bowel diseases + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location Milpitas, CA + Website https://protagonist-inc.com/ * Quintiles Transnational Holdings Inc. NYSE:Q Contract pharmaceutical research and sales organization + Year Invested 2003 + Fund I + Sector Services + Company Status public + Investment Status historic + Location Durham, NC + Website quintiles.com * Reneo Pharmaceuticals, Inc. NasdaqGM:RPHM Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation and may increase production of new mitochondria. + Year Invested 2020 + Fund V + Sector Biopharma + Company Status public + Investment Status current + Location San Diego, CA + Website https://reneopharma.com * Roka Bioscience, Inc. NasdaqGM:ROKA Molecular diagnostics company focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens + Year Invested 2011 + Fund III + Sector Diagnostics + Company Status public + Investment Status historic + Location Warren, NJ + Website http://rokabio.com/ * Seragon Pharmaceuticals, Inc. Biopharmaceutical company focused on developing drugs for the treatment of estrogen receptor dependent breast cancer + Year Invested 2013 + Fund III + Sector Biopharma + Company Status acquired + Investment Status historic + Location San Diego, CA + Website gene.com * Sirion Therapeutics, Inc. Ophthalmic-focused biopharmaceutical company engaged in the discovery, development and commercialization of products for the protection and preservation of eyesight + Year Invested 2007 + Fund II + Sector Biopharma + Company Status acquired + Investment Status historic + Location Tampa, FL + Website * SkinMedica, Inc. Specialty pharmaceutical company focused on development and commercialization of dermatology drugs and cosmeceuticals + Year Invested 2004 + Fund I + Sector Consumer + Company Status acquired + Investment Status historic + Location Carlsbad, CA + Website https://skinmedica.com/ * Sorrento Therapeutics, Inc. NasdaqCM:SRNE Biopharmaceutical company engaged in the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs + Year Invested 2013 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location San Diego, CA + Website https://sorrentotherapeutics.com/ * Spirox, Inc. Medical device company that is focused on developing minimally invasive technologies that improve the quality of life for patients with nasal obstruction + Year Invested 2015 + Fund III + Sector Medical Device + Company Status acquired + Investment Status historic + Location Menlo Park, CA + Website spiroxmed.com * Spruce Biosciences NasdaqGS: SPRB Spruce is a clinical stage biopharmaceutical company developing therapeutics for rare endocrine diseases. Spruce's lead product, tildacerfont, is in late-stage development for classic congenital adrenal hyperplasia (CAH). + Year Invested 2020 + Fund V + Sector Biopharma + Company Status public + Investment Status current + Location San Francisco, CA + Website https://sprucebiosciences.com/ * Spyre Therapeutics NASDAQGS:SYRE Spyre Therapeutics is developing potential best-in-class antibodies, rational therapeutic combinations, and precision immunology approaches with the goal of creating Inflammatory Bowel Disease (IBD) therapies with uncompromising efficacy and convenience. + Year Invested 2023 + Fund V + Sector Biopharma + Company Status public + Investment Status historic + Location Waltham, MA + Website https://spyre.com/ * Syndax Pharmaceuticals, Inc. NasdaqGS:SNDX Biotechnology company developing a pipeline of cancer therapies, including a precision oncology asset for genetically-defined acute leukemias. + Year Invested 2020 + Fund V + Sector Biopharma + Company Status public + Investment Status current + Location Waltham, MA + Website http://syndax.com/ * Synergy Pharmaceuticals Inc. NasdaqGS:SGYP Biopharmaceutical company focused on the development of novel therapies based on the natural human hormone, uroguanylin, to treat gastrointestinal (GI) diseases and disorders + Year Invested 2014 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location New York, NY + Website https://synergypharma.com/ * Syros Pharmaceuticals, Inc. NasdaqGS:SYRS Life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases + Year Invested 2014 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location Watertown, MA + Website https://syros.com/ * T2 Biosystems, Inc. NasdaqGM:TTOO In vitro diagnostics company that has developed a technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies + Year Invested 2011 + Fund III + Sector Diagnostics + Company Status public + Investment Status historic + Location Lexington, MA + Website https://t2biosystems.com/ * Talaris Therapeutics, Inc. NasdaqGM:TALS Talaris Therapeutics, Inc., formerly Regenerex, is a late-clinical stage biotechnology company that is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. Talaris was founded on technology discovered and developed by Dr. Suzanne Ildstad and operates its own cell processing facility in Louisville, KY. Talaris is backed by leading life sciences investors Blackstone Life Sciences, Longitude Capital and Qiming Venture Partners USA and maintains corporate offices in Boston, MA and Louisville, KY. + Year Invested 2020 + Fund V + Sector Biopharma + Company Status public + Investment Status historic + Location Boston, MA + Website https://talaristx.com/ * Topaz Pharmaceuticals, Inc. Specialty pharmaceutical company focused on developing and commercializing treatments primarily for the pediatric and dermatology markets. + Year Invested 2007 + Fund II + Sector Biopharma + Company Status acquired + Investment Status historic + Location Horsham, PA + Website https://sanofi.us/ * TransEnterix, Inc. NYSEMKT:TRXC Medical device company that is focused on the development and commercialization of manual and robotic assisted surgical systems for minimally invasive surgery + Year Invested 2009 + Fund III + Sector Medical Device + Company Status public + Investment Status historic + Location Morrisville, NC + Website https://transenterix.com/ * Treeline Biosciences, Inc. + Year Invested 2021 + Fund V + Sector Biopharma + Company Status private + Investment Status current + Location Stamford, CT + Website https://treelinebiosciences.com/ * TRIA Beauty, Inc. Medical device company developing and commercializing at-home, light-based skincare products + Year Invested 2008 + Fund II + Sector Consumer + Company Status private + Investment Status historic + Location Dublin, CA + Website https://triabeauty.com/ * Verona Pharma plc NasdaqGM:VRNA UK-based biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant medical unmet needs + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location London, UK + Website https://veronapharma.com/ * Versartis, Inc. NasdaqGS:VSAR Endocrine-focused biopharmaceutical company developing novel long-acting recombinant human growth hormone for growth hormone deficiency + Year Invested 2013 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location Redwood City, CA + Website versartis.com * ViewRay, Inc. NasdaqGM:VRAY Medical device company developing advanced radiation therapy technology for the treatment of cancer + Year Invested 2008 + Fund II + Sector Medical Device + Company Status public + Investment Status historic + Location Oakwood Village, OH + Website https://viewray.com/ * Viracta Pharmaceuticals, Inc. NASDAQ: VIRX Precision oncology company focused on the treatment and prevention of virus-associated cancers + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location San Diego, CA + Website https://viracta.com/ * VIVUS, Inc. NasdaqGS:VVUS Biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health + Year Invested 2006 + Fund II + Sector Biopharma + Company Status public + Investment Status historic + Location Mountain View, CA + Website vivus.com * Wugen, Inc. Wugen, Inc., is a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory NK and CAR-T cell therapies to treat a broad range of hematological and solid tumor malignancies. Memory NK cells are hyper-functional, long-lasting immune cells that have evolved to attack cancer and respond to infection. Wugen is harnessing the power of this rare cell population by using its proprietary technologies to create WU-NK-101, currently in development for acute myelogenous leukemia (AML) and solid tumors. Wugen is also advancing WU-CART-007, an allogeneic CAR-T currently in development for T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL). + Year Invested 2021 + Fund V + Sector Biopharma + Company Status private + Investment Status current + Location St. Louis, MO + Website wugen.com * Zavante Therapeutics, Inc. Biopharmaceutical company focused on novel products that address serious unmet medical needs in the hospital + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status acquired + Investment Status historic + Location San Diego + Website zavante.com * ZELTIQ Aesthetics, Inc. NasdaqGS:ZLTQ Medical technology company focused on developing and commercializing products utilizing a controlled cooling technology platform for non-invasive fat reduction + Year Invested 2010 + Fund III + Sector Consumer + Company Status acquired + Investment Status historic + Location Pleasanton, CA + Website https://coolsculpting.com/ * Zosano Pharma Corporation NasdaqCM:ZSAN Biopharmaceutical company developing a novel patch formulation of zolmitriptan for the treatment of acute migraine + Year Invested 2018 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location Fremont, CA + Website https://zosanopharma.com/ * Home * About * Team * Portfolio * News * Contact * Terms of Use © 2024 Aisling Capital. All Rights Reserved. Designed by Shofsky * 489 5th Avenue 10th Floor New York, NY 10017 * T (212) 651-6380 | Toggle navigation * About * Team * Portfolio * News * Contact Portfolio Aisling Capital invests in products, technologies and businesses that advance health. In addition to investing in companies developing pharmaceutical, biotechnology and medical products, Aisling invests in businesses that provide drug development, manufacturing and other important services to the healthcare industry. Portfolio Companies * All * Sector + Biopharma + Consumer + Diagnostics + Medical Device + Services * Geographic Area + Ex-US + Mid-Atlantic + Midwest + Mountain + New England + South + West Coast * Status + Current + Historic * Aclaris Therapeutics, Inc. NasdaqGS: ACRS Specialty pharmaceutical company, focusing on identifying, developing, and commercializing topical drugs to address various needs in dermatology. + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location Malvern, PA + Website https://aclaristx.com/ * Adams Respiratory Therapeutics, Inc. Specialty pharmaceutical company engaged in the development, commercialization and marketing of over-the-counter and prescription drugs for the treatment of respiratory disorders + Year Invested 2001 + Fund I + Sector Consumer + Company Status acquired + Investment Status historic + Location Chester, NJ + Website https://rb.com/ * ADMA Biologics, Inc. NasdaqCM:ADMA Biopharmaceutical company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of infectious diseases + Year Invested 2007 + Fund II + Sector Biopharma + Company Status public + Investment Status current + Location Ramsey, NJ + Website https://admabiologics.com/ * Advion, Inc. Provider of bioanalytical testing equipment to the pharmaceutical industry + Year Invested 2002 + Fund I + Sector Services + Company Status private + Investment Status historic + Location Ithaca, NY + Website https://advion.com/ * Aeglea BioTherapeutics, Inc. NasdaqGM:AGLE Biopharmaceutical company developing human enzyme therapeutics for rare genetic diseases + Year Invested 2018 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location Austin, TX + Website https://aegleabio.com/ * Agile Therapeutics, Inc. NasdaqGM:AGRX Women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products + Year Invested 2012 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location Princeton, NJ + Website https://agiletherapeutics.com/ * Aimmune Therapeutics, Inc. NasdaqGS:AIMT Biopharmaceutical company developing desensitization treatments for food allergies + Year Invested 2015 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location Brisbane, CA + Website https://aimmune.com/ * Ajax Health Medical device platform building a diversified portfolio of emerging medical device companies + Year Invested 2017 + Fund IV + Sector Medical Device + Company Status private + Investment Status current + Location Menlo Park, CA + Website https://ajaxhealth.com/ * Allos Therapeutics, Inc. Biopharmaceutical company engaged in the development and commercialization of anti-cancer therapeutics + Year Invested 2002 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location Westminster, CO + Website https://sppirx.com/ * Ambit Biosciences Corporation Biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat oncology, autoimmune and inflammatory diseases + Year Invested 2001 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location San Diego, CA + Website https://ambitbio.com/ * Antios Therapeutics Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases. Antios is currently developing ATI-2173, aiming to provide chronic hepatitis B-infected patients with a curative combination regimen. + Year Invested 2021 + Fund V + Sector Biopharma + Company Status private + Investment Status historic + Location Atlanta, GA + Website https://antiostherapeutics.com/ * Aragon Pharmaceuticals, Inc. Oncology drug development company focused on novel therapeutics for prostate and breast cancer + Year Invested 2010 + Fund III + Sector Biopharma + Company Status acquired + Investment Status historic + Location New Brunswick, NJ + Website https://jnj.com/ * Archimica Cooperatief U.A. Manufacturer of active pharmaceutical ingredients and late state intermediates for the pharmaceutical industry + Year Invested 2006 + Fund II + Sector Services + Company Status acquired + Investment Status historic + Location Amsterdam, Netherlands + Website euticals.com * Arcus Biosciences, Inc. NYSE:RCUS Biotechnology company developing cancer immunotherapies targeting the adenosine and other oncology pathways + Year Invested 2017 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location Hayward, CA + Website https://arcusbio.com/ * ARMGO Pharma, Inc. Biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics to treat debilitating cardiac, muscular and neurological disorders + Year Invested 2006 + Fund II + Sector Biopharma + Company Status private + Investment Status current + Location Tarrytown, NY + Website http://armgo.com/ * ARMO BioSciences, Inc. NasdaqGS:ARMO Biotechnology company developing immuno-oncology therapies in combination with standard of care or emerging immunotherapies + Year Invested 2018 + Fund IV + Sector Biopharma + Company Status acquired + Investment Status historic + Location Redwood City, CA + Website armobio.com * Ascendis Pharma A/S NasdaqGS:ASND Endocrine-focused biopharmaceutical company developing long-acting human growth hormone for the treatment of pediatric growth hormone deficiency + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location Hellerup, Denmark + Website https://ascendispharma.com/ * Aton Pharma, Inc. Biotechnology company focused on the development of novel treatments for cancer + Year Invested 2002 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location Tarrytown, NY + Website https://merck.com/ * Atreca, Inc. NasdaqGS:BCEL Biotechnology company developing novel oncology therapeutics based on a deep understanding of the human immune response + Year Invested 2018 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location Redwood City, CA + Website https://atreca.com/ * Audentes Therapeutics, Inc. NasdaqGM:BOLD Biotechnology company developing gene therapy-based treatments in several serious, rare diseases + Year Invested 2017 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location San Francisco, CA + Website https://audentestx.com/ * Auxilium Pharmaceuticals, Inc. NasdaqGS:AUXL Specialty pharmaceutical company that develops and markets pharmaceutical products for urology and sexual health + Year Invested 2003 + Fund I + Sector Biopharma + Company Status public + Investment Status historic + Location Chesterbrook, PA + Website auxilium.com * AVANZA Laboratories, LLC Contract research organization that provides GLP complaint drug development services for biotechnology and pharmaceutical firms, and government agencies + Year Invested 2009 + Fund II + Sector Services + Company Status acquired + Investment Status historic + Location Gaithersburg, MD + Website smithersavanza.com * AVROBIO, Inc. NasdaqGS:AVRO Biotechnology company developing lentiviral-based gene therapies to treat lysosomal storage disorders (LSDs) + Year Invested 2018 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location Cambridge, MA + Website https://avrobio.com/ * Axcan Pharma, Inc. Specialty pharmaceutical company focused on the treatment of gastrointestinal disorders + Year Invested 2000 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location Quebec, Canada + Website actavis.com * Barrier Therapeutics, Inc. Specialty pharmaceutical company focused on development and commercialization of dermatology drugs + Year Invested 2002 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location Princeton, NJ + Website http://stiefel.com/ * Bicara Therapeutics Bicara Therapeutics developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. + Year Invested 2023 + Fund V + Sector Biopharma + Company Status private + Investment Status current + Location Cambridge, MA + Website https://bicara.com/ * Bioenvision, Inc. Biotechnology company focused on the development and commercialization of drugs to treat oncology and infectious disease + Year Invested 2002 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location New York, NY + Website genzyme.com * Biohaven Pharmaceuticals Ltd. NYSE:BHVN Biopharmaceutical company developing treatments for orphan neurologic indications and other areas of large unmet medical needs + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location New Haven, CT + Website https://biohavenpharma.com/ * Biomea Fusion, Inc. NasdaqGM:BMEA Biomea Fusion is a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers. Leveraging its extensive expertise in irreversible binding chemistry and development, the Company built its proprietary FUSION System discovery platform to advance a pipeline of novel irreversible, small molecule therapies. The lead product candidate, BMF-219, is an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Biomea Fusion’s goal is to utilize its capabilities and platform to become a leader in developing irreversible small molecules in order to maximize the depth and durability of clinical benefit when treating various cancers. + Year Invested 2020 + Fund V + Sector Biopharma + Company Status public + Investment Status current + Location Redwood City, CA + Website https://biomeafusion.com/ * BridgeBio Pharma LLC NasdaqGS:BBIO Orphan disease drug platform with a robust portfolio of transformative drug programs that address rare diseases across oncology, cardiology, dermatology, neurology and endocrinology + Year Invested 2017 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location Palo Alto, CA + Website https://bridgebio.com/ * Cardiokine, Inc. Biotechnology company developing drugs for the treatment and prevention of cardiovascular diseases + Year Invested 2004 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location Philadelphia, PA + Website https://chiesiusa.com/ * Catalent, Inc. NYSE:CTLT Provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products + Year Invested 2007 + Fund II + Sector Services + Company Status public + Investment Status historic + Location Somerset, NJ + Website https://catalent.com/ * Cempra, Inc. NasdaqGS:CEMP Drug discovery and development company focused on infectious diseases and the treatment of drug-resistant bacteria + Year Invested 2006 + Fund II + Sector Biopharma + Company Status public + Investment Status historic + Location Chapel Hill, NC + Website cempra.com * Chimerix, Inc. NasdaqGM:CMRX Biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need + Year Invested 2013 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location Durham, NC + Website https://chimerix.com/ * Cidara Therapeutics, Inc. NasdaqGM:CDTX Drug discovery and development company focused on devastating fungal infections that often complicate cancer and transplant treatments + Year Invested 2008 + Fund II + Sector Biopharma + Company Status public + Investment Status historic + Location San Diego, CA + Website https://cidara.com/ * Clovis Oncology, Inc. NasdaqGS:CLVS Biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents + Year Invested 2011 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location Boulder, CO + Website https://clovisoncology.com/ * CollaGenex Pharmaceuticals, Inc. Specialty pharmaceutical company that develops and markets proprietary medical therapies to the dermatology market + Year Invested 2001 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location Newton, PA + Website https://galderma.com/ * Colorescience, Inc. Cosmetics company that manufactures and sells mineral-based products + Year Invested 2012 + Fund I + Sector Consumer + Company Status acquired + Investment Status historic + Location Carlsbad, CA + Website https://colorescience.com/ * COMPASS Pathways NASDAQGS: CMPS COMPASS Pathways is a mental health biotechnology company pioneering the development of a new model of psilocybin treatment, in which their proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. + Year Invested 2023 + Fund V + Sector Biopharma + Company Status public + Investment Status current + Location London, UK + Website https://compasspathways.com/ * Cynapsus Therapeutics Inc. NasdaqGM:CYNA Specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson’s disease + Year Invested 2015 + Fund III + Sector Biopharma + Company Status acquired + Investment Status historic + Location Toronto, Canada + Website https://cynapsus.ca/ * Cytos Biotechnology AG SWX:CYTN Biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform + Year Invested 2012 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location Schlieren, Switzerland + Website cytos.com * Dermira, Inc. NasdaqGS:DERM Specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients + Year Invested 2014 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location Redwood City, CA + Website https://dermira.com/ * + Year Invested 2022 + Fund V + Sector Biopharma + Company Status private + Investment Status current + Location Foster City, CA + Website https://drenbio.com/ * Durata Therapeutics, Inc. Pharmaceutical company focused on the development and commercialization of differentiated therapeutic solutions for physicians and providers to advance patient care in infectious disease and acute illnesses + Year Invested 2009 + Fund III + Sector Biopharma + Company Status acquired + Investment Status historic + Location Chicago, IL + Website duratatherapeutics.com * EarLens Corporation Medical device company committed to providing hearing impaired patients a hearing solution that is designed to change the current standard of care for sound performance. + Year Invested 2014 + Fund III + Sector Medical Device + Company Status private + Investment Status historic + Location Menlo Park, CA + Website https://earlens.com/patients/ * Eidos Therapeutics NasdaqGS:EIDX Biopharmaceutical company developing therapies to treat transthyretin amyloidosis (ATTR), primarily in the heart + Year Invested 2018 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location San Francisco, CA + Website https://eidostx.com/ * Elevation Oncology, Inc. NasdaqGM:ELEV Elevation Oncology is a clinical-stage oncology company developing targeted therapies for genetically driven cancers. Elevation's lead product candidate, seribantumab, a HER3 monoclonal antibody, is enrolling a Phase 2 registrational trial for NRG1 fusion-driven cancers. + Year Invested 2019 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location New York, NY + Website https://elevationoncology.com/ * Esperion Therapeutics, Inc. NasdaqGM:ESPR Drug discovery and development company focused on therapies that prevent, treat and reverse cardiovascular and metabolic diseases + Year Invested 2008 + Fund II + Sector Biopharma + Company Status public + Investment Status historic + Location Ann Arbor, MI + Website https://esperion.com/ * F2G Limited Antifungal drug discovery and development company focused on novel therapies to treat life threatening invasive fungal infections + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status private + Investment Status historic + Location Manchester, UK + Website https://f2g.com/ * + Year Invested 2022 + Fund V + Sector Biopharma + Company Status private + Investment Status historic + Location Grove City, OH + Website https://forgebiologics.com/ * Garuda Therapeutics, Inc. Garuda Therapeutics seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants. Garuda's platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible and transgene-free blood stem cell therapies. Like bone marrow transplants, Garuda's technology could provide potentially curative therapies for more than 70 diseases. + Year Invested 2021 + Fund V + Sector Biopharma + Company Status private + Investment Status current + Location Cambridge, MA + Website garudatx.com * Global Blood Therapeutics, Inc. NasdaqGS:GBT Biopharmaceutical company developing novel therapies to improve the lives of patients with serious blood-based disorders + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location South San Francisco, CA + Website https://gbt.com/ * GTx, Inc. NasdaqCM:GTXI Biopharmaceutical company targeting hormone pathways to treat stress urinary incontinence (SUI) in women + Year Invested 2017 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location Memphis, TN + Website gtxinc.com * Harmony Biosciences, LLC NasdaqGM:HRMY Biopharmaceutical company developing and commercializing innovative drugs to address unmet needs for patients with sleep and CNS disorders + Year Invested 2018 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location Plymouth Meeting, PA + Website https://harmonybiosciences.com/ * Ibrutinib Royalty Anti-cancer drug targeting B-cell malignancies + Year Invested 2013 + Fund III + Sector Biopharma + Company Status private + Investment Status historic + Location N/A + Website https://imbruvica.com/ * Infinity Pharmaceuticals, Inc. NasdaqGS:INFI Biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to patients with difficult-to-treat diseases + Year Invested 2012 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location Cambridge, MA + Website https://infi.com/ * Intercept Pharmaceuticals, Inc. NasdaqGS:ICPT Biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing our proprietary bile acid chemistry + Year Invested 2012 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location New York, NY + Website https://interceptpharma.com/ * Intersect ENT, Inc. NasdaqGM:XENT Commercial stage drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions + Year Invested 2014 + Fund III + Sector Medical Device + Company Status public + Investment Status historic + Location Menlo Park, CA + Website propelopens.com * LENSAR, Inc. Leader in next-generation femtosecond laser technology for refractive cataract surgery + Year Invested 2008 + Fund II + Sector Medical Device + Company Status private + Investment Status historic + Location Orlando, FL + Website https://lensar.com/ * Lombard Medical, Inc. NasdaqGM:EVAR Medical technology company specializing in developing, manufacturing and marketing endovascular stent-grafts that address significant unmet needs in the repair of aortic aneurysms + Year Invested 2014 + Fund III + Sector Medical Device + Company Status public + Investment Status historic + Location Oxfordshire, UK + Website https://lombardmedical.com/ * Loxo Oncology, Inc. NasdaqGM:LOXO Biotechnology company developing targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations + Year Invested 2013 + Fund III + Sector Biopharma + Company Status acquired + Investment Status historic + Location Stamford, CT + Website https://loxooncology.com/ * MAP Pharmaceuticals, Inc. Specialty pharmaceutical company developing new therapies based on proprietary drug particle and inhalation technologies + Year Invested 2003 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location Mountain View, CA + Website https://allergan.com/ * Marker Therapeutics, Inc. NasdaqCM:MRKR Biotechnology company developing next-generation T cell-based immunotherapies for cancer + Year Invested 2018 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location Houston, TX + Website https://markertherapeutics.com/ * MKG LLC Medical Knowledge Group is comprised of best-in-class medical communications, health care consulting, and data analytics companies. Guided by strategic insight, creative innovation, and medical acumen, MKG companies specialize in distinct service areas within the health care marketing and communications sector. + Year Invested 2019 + Fund V + Sector Services + Company Status private + Investment Status historic + Location New York, NY + Website https://mkgny.com/ * MEI Pharma, Inc. NasdaqCM:MEIP Oncology company focused on the clinical development of novel therapies for cancer + Year Invested 2013 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location San Diego, CA + Website meipharma.com * Menlo Therapeutics Inc. NasdaqGS:MNLO Biopharmaceutical company developing an oral therapy for the treatment of chronic pruritus associated with various conditions and chronic cough + Year Invested 2017 + Fund IV + Sector Biopharma + Company Status private + Investment Status historic + Location Menlo Park, CA + Website menlotherapeutics.com * Mindful Health Solutions + Year Invested 2024 + Fund V + Sector Services + Company Status private + Investment Status current + Location San Francisco, CA + Website https://mindfulhealthsolutions.com/ * Miramar Labs, Inc. OTC:MRLB Medical device company focused on developing products for dermatologic medical conditions + Year Invested 2011 + Fund III + Sector Medical Device + Company Status acquired + Investment Status historic + Location Sunnyvale, CA + Website https://miradry.com/ * Monte Rosa Therapeutics, Inc. NasdaqGM:GLUE Monte Rosa Therapeutics is a biotechnology company developing molecular glues to degrade disease-causing proteins. The company has developed a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. + Year Invested 2020 + Fund V + Sector Biopharma + Company Status public + Investment Status current + Location Boston, MA + Website https://monterosatx.com/ * Myogen, Inc. Biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders + Year Invested 2001 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location Westminster, CO + Website https://gilead.com/ * Nabriva NasdaqGM:NBRV Biopharmaceutical company developing new antibiotics to treat infectious diseases + Year Invested 2018 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location King of Prussia, PA + Website https://nabriva.com/ * NextWave Pharmaceuticals, Inc. Specialty pharmaceutical company developing extended release OTC and prescription products for children and adults + Year Invested 2007 + Fund II + Sector Biopharma + Company Status acquired + Investment Status historic + Location Cupertino, CA + Website https://pfizer.com/ * Novazyme Pharmaceuticals, Inc. Biotechnology company focused on drugs to treat lysosomal storage diseases + Year Invested 2000 + Fund I + Sector Biopharma + Company Status acquired + Investment Status historic + Location Princeton, NJ + Website https://sanofigenzyme.com/ * Nuvation Bio, Inc. NasdaqGM:NUVB Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. + Year Invested 2019 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location New York, NY + Website https://nuvationbio.com/ * ObsEva SA NasdaqGS:OBSV Biopharmaceutical company developing novel therapeutics in women's health for the treatment of symptoms associated with endometriosis and uterine fibroids + Year Invested 2017 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location Geneva, Switzerland + Website https://obseva.com/ * Oculex Pharmaceuticals, Inc. Ophthalmic drug delivery company with platform technology to facilitate the treatment of major sight-threatening eye diseases and conditions + Year Invested 2002 + Fund I + Sector Medical Device + Company Status acquired + Investment Status historic + Location Sunnyvale, CA + Website https://allergan.com/ * Paratek Pharmaceuticals, Inc. NasdaqGM:PRTK Biopharmaceutical company engaged in the discovery, development and commercialization of antibiotics to save lives and alleviate suffering + Year Invested 2007 + Fund II + Sector Biopharma + Company Status public + Investment Status historic + Location Boston, MA + Website https://paratekpharma.com/ * PellePharm Biotechnology company developing topical therapeutics targeting rare dermatological diseases + Year Invested 2018 + Fund IV + Sector Biopharma + Company Status private + Investment Status historic + Location San Francisco, CA + Website https://pellepharm.com/ * Pernix Therapeutics, Inc. NasdaqGM:PTX Specialty pharmaceutical company primarily focused on the sales, marketing and development of branded pharmaceutical products + Year Invested 2011 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location Houston, TX + Website pernixtx.com * Pharmaron, Inc. Provider of research and development services for pharmaceutical and biotechnological industries worldwide + Year Invested 2006 + Fund II + Sector Services + Company Status private + Investment Status historic + Location Beijing, China + Website https://pharmaron.com/ * Planet Biopharmaceuticals, Inc. Developer and manufacturer of allergenic extracts and other products for the treatment and prevention of allergy + Year Invested 2007 + Fund II + Sector Consumer + Company Status acquired + Investment Status historic + Location Liberty, MO + Website areslifesciences.com * Poseida Therapeutics, Inc. NasdaqGS:PSTX Biopharmaceutical company developing next-generation CAR-T therapies for hematological cancers and solid tumors. + Year Invested 2019 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location San Diego, CA + Website https://poseida.com/ * PowerVision, Inc. Developer of a fluid-controlled intraocular lens + Year Invested 2014 + Fund III + Sector Medical Device + Company Status acquired + Investment Status historic + Location Belmont, CA + Website powervisionlens.com * PreCision Dermatology, Inc. Specialty pharmaceutical company developing, manufacturing and marketing prescription and consumer dermatology products + Year Invested 2012 + Fund III + Sector Biopharma + Company Status acquired + Investment Status historic + Location Cumberland, RI + Website valeant.com * Prolacta Bioscience, Inc. Biopharmaceutical company developing and marketing human milk-based nutritional products for premature infants in the neonatal intensive care unit + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status private + Investment Status historic + Location City of Industry, CA + Website https://prolacta.com/ * Promentis Pharmaceuticals, Inc. Biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system disorders of System XC- + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status private + Investment Status current + Location Milwaukee, WI + Website https://promentispharma.com/ * Protagonist Therapeutics, Inc. NasdaqGM:PTGX Clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs in inflammatory bowel diseases + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location Milpitas, CA + Website https://protagonist-inc.com/ * Quintiles Transnational Holdings Inc. NYSE:Q Contract pharmaceutical research and sales organization + Year Invested 2003 + Fund I + Sector Services + Company Status public + Investment Status historic + Location Durham, NC + Website quintiles.com * Reneo Pharmaceuticals, Inc. NasdaqGM:RPHM Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation and may increase production of new mitochondria. + Year Invested 2020 + Fund V + Sector Biopharma + Company Status public + Investment Status current + Location San Diego, CA + Website https://reneopharma.com * Roka Bioscience, Inc. NasdaqGM:ROKA Molecular diagnostics company focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens + Year Invested 2011 + Fund III + Sector Diagnostics + Company Status public + Investment Status historic + Location Warren, NJ + Website http://rokabio.com/ * Seragon Pharmaceuticals, Inc. Biopharmaceutical company focused on developing drugs for the treatment of estrogen receptor dependent breast cancer + Year Invested 2013 + Fund III + Sector Biopharma + Company Status acquired + Investment Status historic + Location San Diego, CA + Website gene.com * Sirion Therapeutics, Inc. Ophthalmic-focused biopharmaceutical company engaged in the discovery, development and commercialization of products for the protection and preservation of eyesight + Year Invested 2007 + Fund II + Sector Biopharma + Company Status acquired + Investment Status historic + Location Tampa, FL + Website * SkinMedica, Inc. Specialty pharmaceutical company focused on development and commercialization of dermatology drugs and cosmeceuticals + Year Invested 2004 + Fund I + Sector Consumer + Company Status acquired + Investment Status historic + Location Carlsbad, CA + Website https://skinmedica.com/ * Sorrento Therapeutics, Inc. NasdaqCM:SRNE Biopharmaceutical company engaged in the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs + Year Invested 2013 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location San Diego, CA + Website https://sorrentotherapeutics.com/ * Spirox, Inc. Medical device company that is focused on developing minimally invasive technologies that improve the quality of life for patients with nasal obstruction + Year Invested 2015 + Fund III + Sector Medical Device + Company Status acquired + Investment Status historic + Location Menlo Park, CA + Website spiroxmed.com * Spruce Biosciences NasdaqGS: SPRB Spruce is a clinical stage biopharmaceutical company developing therapeutics for rare endocrine diseases. Spruce's lead product, tildacerfont, is in late-stage development for classic congenital adrenal hyperplasia (CAH). + Year Invested 2020 + Fund V + Sector Biopharma + Company Status public + Investment Status current + Location San Francisco, CA + Website https://sprucebiosciences.com/ * Spyre Therapeutics NASDAQGS:SYRE Spyre Therapeutics is developing potential best-in-class antibodies, rational therapeutic combinations, and precision immunology approaches with the goal of creating Inflammatory Bowel Disease (IBD) therapies with uncompromising efficacy and convenience. + Year Invested 2023 + Fund V + Sector Biopharma + Company Status public + Investment Status historic + Location Waltham, MA + Website https://spyre.com/ * Syndax Pharmaceuticals, Inc. NasdaqGS:SNDX Biotechnology company developing a pipeline of cancer therapies, including a precision oncology asset for genetically-defined acute leukemias. + Year Invested 2020 + Fund V + Sector Biopharma + Company Status public + Investment Status current + Location Waltham, MA + Website http://syndax.com/ * Synergy Pharmaceuticals Inc. NasdaqGS:SGYP Biopharmaceutical company focused on the development of novel therapies based on the natural human hormone, uroguanylin, to treat gastrointestinal (GI) diseases and disorders + Year Invested 2014 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location New York, NY + Website https://synergypharma.com/ * Syros Pharmaceuticals, Inc. NasdaqGS:SYRS Life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases + Year Invested 2014 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location Watertown, MA + Website https://syros.com/ * T2 Biosystems, Inc. NasdaqGM:TTOO In vitro diagnostics company that has developed a technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies + Year Invested 2011 + Fund III + Sector Diagnostics + Company Status public + Investment Status historic + Location Lexington, MA + Website https://t2biosystems.com/ * Talaris Therapeutics, Inc. NasdaqGM:TALS Talaris Therapeutics, Inc., formerly Regenerex, is a late-clinical stage biotechnology company that is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. Talaris was founded on technology discovered and developed by Dr. Suzanne Ildstad and operates its own cell processing facility in Louisville, KY. Talaris is backed by leading life sciences investors Blackstone Life Sciences, Longitude Capital and Qiming Venture Partners USA and maintains corporate offices in Boston, MA and Louisville, KY. + Year Invested 2020 + Fund V + Sector Biopharma + Company Status public + Investment Status historic + Location Boston, MA + Website https://talaristx.com/ * Topaz Pharmaceuticals, Inc. Specialty pharmaceutical company focused on developing and commercializing treatments primarily for the pediatric and dermatology markets. + Year Invested 2007 + Fund II + Sector Biopharma + Company Status acquired + Investment Status historic + Location Horsham, PA + Website https://sanofi.us/ * TransEnterix, Inc. NYSEMKT:TRXC Medical device company that is focused on the development and commercialization of manual and robotic assisted surgical systems for minimally invasive surgery + Year Invested 2009 + Fund III + Sector Medical Device + Company Status public + Investment Status historic + Location Morrisville, NC + Website https://transenterix.com/ * Treeline Biosciences, Inc. + Year Invested 2021 + Fund V + Sector Biopharma + Company Status private + Investment Status current + Location Stamford, CT + Website https://treelinebiosciences.com/ * TRIA Beauty, Inc. Medical device company developing and commercializing at-home, light-based skincare products + Year Invested 2008 + Fund II + Sector Consumer + Company Status private + Investment Status historic + Location Dublin, CA + Website https://triabeauty.com/ * Verona Pharma plc NasdaqGM:VRNA UK-based biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant medical unmet needs + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location London, UK + Website https://veronapharma.com/ * Versartis, Inc. NasdaqGS:VSAR Endocrine-focused biopharmaceutical company developing novel long-acting recombinant human growth hormone for growth hormone deficiency + Year Invested 2013 + Fund III + Sector Biopharma + Company Status public + Investment Status historic + Location Redwood City, CA + Website versartis.com * ViewRay, Inc. NasdaqGM:VRAY Medical device company developing advanced radiation therapy technology for the treatment of cancer + Year Invested 2008 + Fund II + Sector Medical Device + Company Status public + Investment Status historic + Location Oakwood Village, OH + Website https://viewray.com/ * Viracta Pharmaceuticals, Inc. NASDAQ: VIRX Precision oncology company focused on the treatment and prevention of virus-associated cancers + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status public + Investment Status current + Location San Diego, CA + Website https://viracta.com/ * VIVUS, Inc. NasdaqGS:VVUS Biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health + Year Invested 2006 + Fund II + Sector Biopharma + Company Status public + Investment Status historic + Location Mountain View, CA + Website vivus.com * Wugen, Inc. Wugen, Inc., is a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory NK and CAR-T cell therapies to treat a broad range of hematological and solid tumor malignancies. Memory NK cells are hyper-functional, long-lasting immune cells that have evolved to attack cancer and respond to infection. Wugen is harnessing the power of this rare cell population by using its proprietary technologies to create WU-NK-101, currently in development for acute myelogenous leukemia (AML) and solid tumors. Wugen is also advancing WU-CART-007, an allogeneic CAR-T currently in development for T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL). + Year Invested 2021 + Fund V + Sector Biopharma + Company Status private + Investment Status current + Location St. Louis, MO + Website wugen.com * Zavante Therapeutics, Inc. Biopharmaceutical company focused on novel products that address serious unmet medical needs in the hospital + Year Invested 2016 + Fund IV + Sector Biopharma + Company Status acquired + Investment Status historic + Location San Diego + Website zavante.com * ZELTIQ Aesthetics, Inc. NasdaqGS:ZLTQ Medical technology company focused on developing and commercializing products utilizing a controlled cooling technology platform for non-invasive fat reduction + Year Invested 2010 + Fund III + Sector Consumer + Company Status acquired + Investment Status historic + Location Pleasanton, CA + Website https://coolsculpting.com/ * Zosano Pharma Corporation NasdaqCM:ZSAN Biopharmaceutical company developing a novel patch formulation of zolmitriptan for the treatment of acute migraine + Year Invested 2018 + Fund IV + Sector Biopharma + Company Status public + Investment Status historic + Location Fremont, CA + Website https://zosanopharma.com/ * Home * About * Team * Portfolio * News * Contact * Terms of Use © 2024 Aisling Capital. All Rights Reserved. Designed by Shofsky * 489 5th Avenue 10th Floor New York, NY 10017 * T (212) 651-6380 |
For now, Differences are performed on text, not graphically, only the latest screenshot is available.
Screenshot requires Playwright/WebDriver enabled